top of page

The Founder's Story

Jeffrey Carlisle is also the founder of Fluidnet (Ivenix), which sold to Fresenius in 2022. He holds many patents for infusion therapy products, starting in 1978. Jeffrey began his career by leading the development of groundbreaking designs in cardiography and peritoneal dialysis. He also launched Bard Electrophysiology, which sold to Boston Scientific.

  • LinkedIn

A winning team collaborating to
transform infusion care

Success at prominent medical device and analytics companies

Hewlett-Packard; American Hospital Supply; FluidSense; Ivenix; IVAC; Home Healthcare of America; CORAM; Alaris; BD; Delphi; Harvard Apparatus; CR Bard; Medex; Smiths Medical; Koru; DEKA; IVAC; IMED; Baxter; OptionCare;Minimed; Live Ramp

Experts across all critical disciplines

Engineering: systems, mechanical, industrial, electronics, embedded, reliability, database, UX; Manufacturing; Operations, Finance; Regulatory; IP; Marketing; Clinical: RN, Pharm; Data analytics; 

World Class Partners

We have partnered with well established leaders in advanced manufacturing, distribution, web services, and global R&D leaders. This lets our small team focus on inventing and lean on the experiences of others. We know where to go to get the job done and done right.

bottom of page